GleamWall
中文EN

ANNX Annexon, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1528115 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.9%
TTM EPS YoY28.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-130.8%
ROA-83.0%
ROIC (approx.)-293.6%
Asset turnover—

Leverage & solvency

Liabilities / assets43.0%
Debt / equity0.35x
Current ratio5.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$41.37M$46.59M$35.79M$42.66M$49.70M$44.16M$48.18M$43.35M
SG&A expense$10.87M$10.64M$10.27M$7.60M$7.32M$7.57M$9.23M$9.12M
Operating income-$52.24M-$57.23M-$46.05M-$50.26M-$57.02M-$51.73M-$57.41M-$52.48M
Interest expense$833,000———$0———
Net income-$51.22M-$55.35M-$44.14M-$48.26M-$54.92M-$49.16M-$54.36M-$48.59M
EBITDA-$51.71M-$56.69M-$45.51M-$49.72M-$56.47M-$51.19M-$56.87M-$51.94M
EPS (basic)-0.25-0.28-0.23—-0.37-0.34-0.37—
EPS (diluted)-0.25-0.28-0.23—-0.37-0.34-0.37—
Weighted avg. shares (diluted)204.65M201.00M194.20M—149.12M148.32M148.11M—
Balance sheet
Cash & equivalents$102.39M$199.27M$175.21M$162.05M$140.45M$133.32M$98.15M$50.53M
Short-term investments$110.98M$9.97M$49.82M$76.29M$49.30M$94.73M$166.57M$262.52M
Current assets$217.90M$212.76M$228.27M$242.19M$192.82M$230.62M$268.16M$316.46M
PP&E, net$9.16M$9.68M$10.11M$10.62M$11.15M$11.65M$12.19M$12.64M
Total assets$250.41M$246.07M$262.89M$277.57M$229.14M$264.57M$303.03M$350.07M
Current liabilities$37.66M$38.48M$35.94M$42.63M$43.58M$40.64M$33.55M$30.51M
Long-term debt$49.34M——$0————
Total debt$49.34M——$0————
Total liabilities$107.61M$60.01M$58.35M$65.92M$67.70M$65.56M$59.24M$56.97M
Shareholders' equity$142.79M$186.06M$204.53M$211.65M$161.44M$199.02M$243.79M$293.11M
Net debt-$53.05M——-$162.05M————
Shares outstanding———149.36M———109.38M
Cash flow statement
Operating cash flow-$48.68M-$48.01M-$46.80M-$45.93M-$52.30M-$38.07M-$50.05M-$36.02M
Capital expenditure$0$137,000$0$0$48,000$15,000$74,000$6,000
Free cash flow-$48.68M-$48.14M-$46.80M-$45.93M-$52.35M-$38.09M-$50.13M-$36.02M
Investing cash flow-$100.50M$39.97M$27.06M-$26.52M$45.87M$73.08M$97.62M$1.01M
Financing cash flow$52.30M$32.10M$32.90M$95.08M$13.56M$153,000$59,000$4.97M
Depreciation & amortization$525,000$540,000$539,000$543,000$546,000$540,000$537,000$537,000
Stock-based compensation$5.11M$4.81M$4.16M$3.31M$3.83M$4.21M$5.08M$5.22M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.